** Shares of drug developer Eton Pharmaceuticals ETON.O fall ~3% to $12.58
** ETON says it has out-licensed the non-U.S. commercial rights for its rare disease drug, Increlex, to Spain's Esteve Pharmaceuticals
** Esteve will pay Eton 4 million euros ($4.32 million) upfront for the licensing rights lasting up to ten years
** ETON will still make the product and sell it to Esteve at a fixed price
** Esteve also receives an option to permanently acquire the international rights in the future for up to 6 million euros
** Increlex is used to treat growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency
** Including session move, ETON fell 2.6% YTD
($1 = 0.9267 euros)
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。